Celiac Index

Training the immune system to ignore gluten — the most ambitious treatment strategy, aiming to cure rather than manage celiac disease.

Tolerance induction therapies aim to re-educate the immune system so that CD4+ T cells no longer respond to gliadin peptides as threats. If successful, a patient could eat gluten without triggering an immune response — making it the only approach that could constitute a genuine cure, not just management.

The concept is analogous to allergen immunotherapy (allergy shots) — where incremental exposure to an allergen gradually desensitises the immune system.

The Challenge

Celiac disease involves highly specific, well-characterised T cell responses to defined gliadin epitopes presented on HLA-DQ2 or DQ8. This specificity is both an obstacle (the immune memory is precise and persistent) and an opportunity (you know exactly what to target).

Key Candidates

Nexvax2 (ImmusanT)

A peptide vaccine containing the three dominant DQ2.5-restricted gliadin epitopes
Delivered by intradermal injection
Mechanism: designed to induce regulatory T cells (Tregs) that suppress the gluten-reactive T cell response
Phase 2 trial (~2019): failed — trial was stopped early after patients receiving the active vaccine experienced worse symptoms than placebo during a gluten challenge. The dose may have been too high, activating rather than tolerising T cells.
Lessons learned: the right dose and route for tolerance vs activation is critical; failed, but the T cell epitope targeting approach remains valid

TAK-101

Gliadin-loaded nanoparticles designed to induce antigen-specific tolerance without directly provoking the same kind of peptide-reactive flare risk seen with earlier vaccine-style approaches
Early studies suggested biologic activity during gluten challenge, including reduced gliadin-specific IFN-γ responses and better preservation of mucosal architecture than placebo
Conceptually important because it keeps the tolerance goal while changing the delivery system

KAN-101 (Anokion)

Liver-targeted antigen delivery intended to induce gluten tolerance through a more physiologic tolerogenic route
Gluten antigens are coupled to a molecule that directs them to the liver
Liver-targeted antigen presentation preferentially induces tolerance (the liver is immunologically "tolerogenic" — it sees gut-derived antigens and tends to suppress responses rather than activate them)
A newer 2026 beyond-GFD review reinforces that KAN-101 has shown encouraging early safety/tolerability characteristics, but remains early-stage rather than clinically proven

How It Differs from Other Approaches

Treatment	What It Targets	Reversibility
GFD	Removes the trigger	Lifelong; symptoms return on gluten
glutenases	Destroys gluten in gut	Only works while taking the drug
Larazotide	Blocks gluten uptake	Only works while taking the drug
IL-15 inhibitors	Suppresses innate immune response	Only works while taking the drug
Tolerance induction	Reprograms immune memory	Potentially permanent — could allow gluten consumption

Regulatory T Cells (Tregs)

The intended outcome of successful tolerance induction is expansion of antigen-specific regulatory T cells (Tregs) — T cells that actively suppress the gluten-reactive effector T cell population. Tregs are the immune system's "off switch" for specific responses.

Source Basis

Current synthesis also incorporates:

raw/PIIS0016508524004165.pdf (How Future Pharmacologic Therapies for Celiac Disease Will Complement the Gluten-Free Diet, 2024), especially for framing tolerance induction as the most ambitious but also the most biologically difficult strategy
raw/biomedicines-14-00029-v2.pdf (Rethinking Celiac Disease Management: Treatment Approaches Beyond the Gluten-Free Diet, 2026), especially for TAK-101, KAN-101, and the more mature post-Nexvax2 framing of tolerance research
raw/cogas-41-124.pdf (New therapies in celiac disease, 2025), especially for updated KAN-101, TAK-101, and Nexvax2 trial-status context

Referenced In

research_plan | research | glossary